Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $161.6600 (-2.94%) ($160.8800 - $166.2800) on Mon. Jan. 9, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 1.12% (three month average) | RSI | 47 | Latest Price | $161.6600(-2.94%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ABBV advances 0.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(22%) IBB(21%) SPLV(19%) XLP(18%) VYM(17%) | Factors Impacting ABBV price | ABBV will decline at least -0.56% in a week (0% probabilities). XLC(-13%) IPO(-13%) EDOC(-9%) BWX(-8%) VXX(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.56% (StdDev 1.12%) | Hourly BBV | -2 () | Intraday Trend | -2.6% | | | |
|
Resistance Level | $162.85 | 5 Day Moving Average | $163.55(-1.16%) | 10 Day Moving Average | $162.99(-0.82%) | 20 Day Moving Average | $162.85(-0.73%) | To recent high | -2.9% | To recent low | 16.9% | Market Cap | $285.214b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |